The emerging role of dupilumab in dermatological indications

References

• Szalus K, Trzeciak M, Nowicki RJ. JAK-STAT Inhibitors in atopic dermatitis from pathogenesis to clinical trials results. Microorganisms. 2020;8(11):E1743.
   PubMed Web of Science ®Google Scholar
• Gooderham MJ, Hong HC, Eshtiaghi P, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S28–S36. PMID: 29471919.
   PubMed Web of Science ®Google Scholar
• Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017;139(4S):S65–S76.
   PubMed Web of Science ®Google Scholar
• Seegräber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018 May;11(5):467–474. Epub 2018 Mar 20. PMID: 29557246.
   PubMed Web of Science ®Google Scholar
• Regeneron pharmaceuticals. DUPIXENTVR prescribing information. Tarrytown, NY; 2018 October. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761055s007lbl.pdf 
   Google Scholar
• Beck LA, Thac¸i D, Hamilton JD, et al. Dupilumab treatment in adults Dermatol Ther (Heidelb) with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371(2):130–139.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus Placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335–2348.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, De Bruin-weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287–2303.
   PubMed Web of Science ®Google Scholar
• De Bruin-weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFE´). Br J Dermatol. 2018;178(5):1083–1101.
   PubMed Web of Science ®Google Scholar
• Napolitano M, Napolitano M, Argenziano G, et al. DADE—Dupilumab for atopic dermatitis of the elderly study group. Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study. J Eur Acad Dermatol Venereol. 2020 Dec 17;34(11):e701-e703.
   PubMedGoogle Scholar
• Nettis E, Fabbrocini G, Ortoncelli M, et al. Long-term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients. Br J Dermatol. 2020 Sep 30;184(3):561–563. Epub ahead of print. PMID: 32998177.
   PubMedGoogle Scholar
• Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018 Jun 28;378(26):2475–2485. Epub 2018 May 21. PMID: 29782224.
   PubMed Web of Science ®Google Scholar
• Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019 Nov 2;394(10209):1638–1650. Epub 2019 Sep 19. Erratum in: Lancet. 2019 Nov 2;394(10209):1618. PMID: 31543428.
   PubMed Web of Science ®Google Scholar
• De Bruin-weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018 May;178(5):1083–1101. Epub 2018 Mar 25. PMID: 29193016.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 Dec 15;375(24):2335–2348. Epub 2016 Sep 30. PMID: 27690741.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the 467 definition, classification, diagnosis and management of urticaria. Allergy 2018;73(7):1393–1414.
   PubMed Web of Science ®Google Scholar
• Schmetzer O, Lakin E, Topal FA, et al. IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2018;142(3):876–882.
   PubMed Web of Science ®Google Scholar
• Sabroe RA, Fiebiger E, Francis DM, et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol. 2002 Sep;110(3):492–499. PMID: 12209101.
   PubMed Web of Science ®Google Scholar
• Sheikh J. Autoantibodies to the high-affinity IgE receptor in chronic urticaria: how important are they? Curr Opin Allergy Clin Immunol. 2005 Oct;5(5):403–407.
   PubMed Web of Science ®Google Scholar
• Boyman O, Kaegi C, Akdis M, et al. EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders. Allergy. 2015 Jul;70(7):727–754. Epub 2015 Apr 24. PMID: 25819018.
   PubMed Web of Science ®Google Scholar
• Lee JK, Simpson RS. Dupilumab as a novel therapy for difficult to treat chronic spontaneous urticaria. J Allergy Clin Immunol Pract. 2019 May–Jun;7(5):1659–1661. e1. Epub 2018 Nov 27. PMID: 30496828.
   PubMed Web of Science ®Google Scholar
• Ferrucci S, Benzecry V, Berti E, et al. Rapid disappearance of both severe atopic dermatitis and cold urticaria following dupilumab treatment. Clin Exp Dermatol. 2020 Apr;45(3):345–346. Epub 2019 Sep 12. PMID: 31437869.
   PubMed Web of Science ®Google Scholar
• Föhr J, Herbst M, Jahn S. Therapie von urtikaria und atopischer dermatitis beieinerpatientinmit Dupilumab [Treatment of simultaneously occurring urticaria and atopic dermatitis with dupilumab]. Hautarzt. 2020 Aug 27. German. doi:https://doi.org/10.1007/s00105-020-04675-3.
   Google Scholar
• Goodman B, Jariwala S. Dupilumab as a novel therapy to treat adrenergic urticaria. Ann Allergy Asthma Immunol. 2020 Jul 1;S1081-1206(20):30441–30445. Epub ahead of print. PMID: 32621993; PMCID: PMC7327453.
   Google Scholar
• ClinicalTrials.gov. Dupilumab for the treatment of chronic spontaneous urticaria in patients who remain symptomatic despite the use of H1 antihistamine and who are naïve to, intolerant of, or incomplete responders to omalizumab (CUPID). U.S. National Library of Medicine. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04180488. [ Last accessed 29 December 2020]
   Google Scholar
• ClinicalTrials.gov. Dupilumab in chronic spontaneous urticaria (DUPICSU) U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03749135.
   Google Scholar
• ClinicalTrials.gov. Cholinergic urticaria—Efficacy of dupilumab (CHED). U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03749148.
   Google Scholar
• Zeidler C, Yosipovitch G, Ständer S. Prurigo nodularis and its management. Dermatol Clin. 2018;36(3):189–197.
   PubMed Web of Science ®Google Scholar
• Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2017;32(7):1059–1065.
   PubMed Web of Science ®Google Scholar
• Spring P, Gschwind I, Gilliet M. Prurigo nodularis: retrospective study of 13 cases managed with methotrexate. Clin Exp Dermatol. 2014;39(4):468–473.
   PubMed Web of Science ®Google Scholar
• Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch. cell. 2017 Sep 21;171(1):217–228. e13. Epub 2017 Sep 7. PMID: 28890086; PMCID: PMC5658016.•• The authors provided an excellent overview of the phenotypes of atopic dermatitis in the adult patients.
   PubMed Web of Science ®Google Scholar
• Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol. 2011 Nov;165(5):990–996. Epub 2011 Sep 29. PMID: 21711341.
   PubMed Web of Science ®Google Scholar
• Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. Epub 2017 Jan 10. PMID: 28071589 J Investig Allergol Clin Immunol. 2017;272:78–88.
   PubMed Web of Science ®Google Scholar
• Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2020 Dec 11:1–11. Epub ahead of print. PMID: 33191806. DOI: https://doi.org/10.1080/17512433.2021.1852080
   Google Scholar
• Granstein RD, Wagner JA, Stohl LL, et al. Calcitonin gene-related peptide: key regulator of cutaneous immunity. Acta Physiol (Oxf). 2015;213(3):586–594.
   PubMed Web of Science ®Google Scholar
• Tanis R, Ferenczi K, Payette M. Dupilumab treatment for prurigo nodularis and pruritis. J Drugs Dermatol. 2019 Sep 1;18(9):940–942. PMID: 31524352.
   PubMed Web of Science ®Google Scholar
• Mollanazar NK, Elgash M, Weaver L, et al. Reduced itch associated with dupilumab treatment in 4 patients with prurigo nodularis. JAMA Dermatol. 2019 Jan 1;155(1):121–122. PMID: 30427989.
   PubMed Web of Science ®Google Scholar
• Beck KM, Yang EJ, Sekhon S, et al. Dupilumab treatment for generalized prurigo nodularis. JAMA Dermatol. 2019 Jan 1;155(1):118–120. PMID: 30427994.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Tauber M, et al. Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients. J Eur AcadDermatolVenereol. 2020 Feb;34(2):e74–e76. Epub 2019 Oct 17. PMID: 31529718.
   PubMed Web of Science ®Google Scholar
• Giura MT, Viola R, Fierro MT, et al. Efficacy of dupilumab in prurigo nodularis in elderly patient. Dermatol Ther. 2020 Jan;33(1):e13201. Epub 2019 Dec 28. PMID: 31856368.
   PubMed Web of Science ®Google Scholar
• Holm JG, Agner T, Sand C, et al. Dupilumab for prurigo nodularis: case series and review of the literature. Dermatol Ther. 2020 Mar;33(2):e13222. Epub 2020 Jan 16. PMID: 31917498.
   PubMed Web of Science ®Google Scholar
• Wieser JK, Mercurio MG, Somers K. Resolution of treatment-refractory prurigo nodularis with dupilumab: a case series. Cureus. 2020 Jun 21;12(6):e8737. PMID: 32714676; PMCID: PMC7377018.
   PubMed Web of Science ®Google Scholar
• Almustafa ZZ, Weller K, Autenrieth J, et al. Dupilumab in treatment of chronic prurigo: a case series and literature review. Acta Derm Venereol. 2019 Sep 1;99(10):905–906. PMID: 31233177.
   PubMed Web of Science ®Google Scholar
• Calugareanu A, Jachiet M, Lepelletier C, et al. Dramatic improvement of generalized prurigo nodularis with dupilumab. J Eur AcadDermatolVenereol. 2019 Aug;33(8):e303–e304. Epub 2019 May 8. PMID: 30893496.
   PubMed Web of Science ®Google Scholar
• Rambhia PH, Levitt JO. Recalcitrant prurigo nodularis treated successfully with dupilumab. JAAD Case Rep. 2019 May 8;5(5):471–473. PMID: 31192991; PMCID: PMC6510953.
   PubMedGoogle Scholar
• Romano C. Safety and effectiveness of dupilumab in prurigo nodularis. J Investig Allergol Clin Immunol. 2020 Jun; 230. Epub ahead of print. PMID 32573461.
   Google Scholar
• Ferrucci S, Tavecchio S, Berti E, et al. Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy. J Dermatolog Treat. 2019 Sep 2:1–2 Epub ahead of print. PMID: 31442084. DOI:https://doi.org/10.1080/09546634.2019.1659479.
   Web of Science ®Google Scholar
• Napolitano M, Fabbrocini G, Scalvenzi M, et al. Effectiveness of dupilumab for the treatment of generalized prurigo nodularis phenotype of adult atopic dermatitis. Dermatitis. 2020 Jan/ Feb;31(1):81–84. PMID: 31517666.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME). U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04183335.
   Google Scholar
• ClinicalTrials.gov. Study of dupilumab for the treatment of patients with prurigo nodularis, inadequately controlled on topical prescription therapies or when those therapies are not advisable (PRIME2). U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT04202679.
   Google Scholar
• Ständer S, Weisshaar E, Mettang T, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol. 2007;87(4):291–294. PMID: 17598029.
   PubMed Web of Science ®Google Scholar
• Weisshaar E, Szepietowski JC, Dalgard FJ, et al. European S2k Guideline on Chronic Pruritus. Acta Derm Venereol. 2019 Apr 1;99(5):469–506. PMID: 30931482.
   PubMed Web of Science ®Google Scholar
• Whang KA, Khanna R, Williams KA, et al. Health-related quality of life and economic burden of chronic pruritus. J Invest Dermatol. 2020 Sep 14;S0022-202(20):32063–32067. Epub ahead of print. PMID: 32941916.
   Google Scholar
• Brummer GC, Wang LT, Sontheimer RD. A possible role for dupilumab (Dupixent) in the management of idiopathic chronic eczematous eruption of aging. Dermatol Online J. 2018 Feb 15;24(2), 13030/qt55z1f6xh. PMID: 29630150.
   PubMedGoogle Scholar
• Zhai LL, Savage KT, Qiu CC, et al. Chronic pruritus responding to dupilumab—a case series. Medicines (Basel). 2019 Jun 29;6(3):72. PMID: 31261951; PMCID: PMC6789555.
   Google Scholar
• Yang EJ, Murase JE. Recalcitrant anal and genital pruritus treated with dupilumab. Int J Womens Dermatol. 2018 Oct 4;4(4):223–226. PMID: 30627621; PMCID: PMC6322158.
   PubMedGoogle Scholar
• Silverberg JI, Brieva J. A successful case of dupilumab treatment for severe uremic pruritus. JAAD Case Rep. 2019 Apr 3;5(4):339–341. PMID: 30993160; PMCID: PMC6449741.
   PubMedGoogle Scholar
• Stanger R, Rivera-Oyola R, Lebwohl M. Dupilumab as a treatment for generalized idiopathic pruritus: a report of two cases. Br J Dermatol. 2020 Jun;182(6):1494–1495. Epub 2020 Feb 12. PMID: 31883341.
   PubMed Web of Science ®Google Scholar
• Study on dupilumab for the treatment of moderate to severe chronic hepatic pruritus. [cited 2020 Dec 29]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT04256759.
   Google Scholar
• Miyamoto D, Santi CG, Aoki V, et al. Bullous pemphigoid. An Bras Dermatol. 2019 Mar-Apr;94(2):133–146. Epub 2019 May 9. PMID: 31090818; PMCID: PMC6486083.
   PubMed Web of Science ®Google Scholar
• Russo R, Cozzani E, Gasparini PA. Targeting interleukin 4 receptor α: a new approach to the treatment of cutaneous autoimmune bullous diseases? Dermatol Ther. 2020 Jan;33(1):e13190. Epub 2020 Jan 2. PMID: 31863534; PMCID: PMC7154653.
   PubMed Web of Science ®Google Scholar
• Maglie R, Hertl M. Pharmacological advances in pemphigoid. CurrOpinPharmacol. 2019 Jun;46:34–43. Epub 2019 Feb 13. PMID: 30769277.
   Google Scholar
• Tavakolpour S, Tavakolpour V. Interleukin 4 inhibition as a potential therapeutic in pemphigus. Cytokine. 2016 Jan;77:189–195. Epub 2015 Oct 2. PMID: 26440137.
   PubMed Web of Science ®Google Scholar
• Kaye A, Gordon SC, Deverapalli SC, et al. Dupilumab for the treatment of recalcitrant bullous pemphigoid. JAMA Dermatol. 2018 Oct 1;154(10):1225–1226. PMID: 30140849.
   PubMed Web of Science ®Google Scholar
• Seidman JS, Eichenfield DZ, Orme CM. Dupilumab for bullous pemphigoid with intractable pruritus. Dermatol Online J. 2019 Nov 15;25(11), 13030/qt25q9w6r9. PMID: 32045153.
   PubMedGoogle Scholar
• Abdat R, Waldman RA, De Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol. 2020 Jul;83(1):46–52. Epub 2020 Mar 13. PMID: 32179082.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A study to evaluate the efficacy and safety ofdupilumabin adult patients withbullous pemphigoid (LIBERTY-BP). U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04206553.
   Google Scholar
• Fabbrocini G, Panariello L, De Vita V, et al. Quality of life in alopecia areata: a disease-specific questionnaire. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e276–281. Epub 2012 Jul 3. PMID: 22759244.
   PubMed Web of Science ®Google Scholar
• Ito T, Kageyama R, Nakazawa S, et al. Understanding the significance of cytokines and chemokines in the pathogenesis of alopecia areata. Exp Dermatol. 2020 Aug;29(8):726–732. Epub 2020 Jul 3. PMID: 32533873.
   PubMed Web of Science ®Google Scholar
• Smogorzewski J, Sierro T, Compoginis G, et al. Remission of alopecia universalis in a patient with atopic dermatitis treated with dupilumab. JAAD Case Rep. 2019 Jan 12;5(2):116–117. PMID: 30671524; PMCID: PMC6330370.
   PubMedGoogle Scholar
• Magdaleno-Tapial J, Valenzuela-Oñate C, García-Legaz-Martínez M, et al. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature. Australas J Dermatol. 2020 May;61(2):e223–e225. Epub 2019 Nov 25. PMID: 31766073.
   PubMed Web of Science ®Google Scholar
• Uchida H, Kamata M, Watanabe A, et al. Dupilumab improved alopecia areata in a patient with atopic dermatitis: a case report. Acta Derm Venereol. 2019 Jun 1;99(7):675–676. PMID: 30938821.
   PubMed Web of Science ®Google Scholar
• Darrigade AS, Legrand A, Andreu N, et al. Dual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areata. Br J Dermatol. 2018 Aug;179(2):534–536. Epub 2018 Jun 15. PMID: 29710431.
   PubMed Web of Science ®Google Scholar
• Muto J, Yoshida S, Ooi C, et al. Dupilumab treatment of atopic dermatitis leading to successful treatment of alopecia universalis: a Japanese case report. J Dermatol. 2020 Oct 7;48(2):e72-e73. Epub ahead of print. PMID: 33029817.
   PubMed Web of Science ®Google Scholar
• Penzi LR, Yasuda M, Manatis-Lornell A, et al. Hair regrowth in a patient with long-standing alopecia totalis and atopic dermatitis treated with dupilumab. JAMA Dermatol. 2018 Nov 1;154(11):1358–1360. PMID: 30304403.
   PubMed Web of Science ®Google Scholar
• Ludriksone L, Elsner P, Schliemann S. Simultaneous effectiveness of dupilumab in atopic dermatitis and alopecia areata in two patients. J Dtsch Dermatol Ges. 2019 Dec;17(12):1278–1280. Epub 2019 Dec 12. PMID: 31829527.
   Web of Science ®Google Scholar
• Szekely S, Vaccari D, Salmaso R, et al. Onset of Schamberg’s disease and resolution of alopecia areata during treatment of atopic dermatitis with dupilumab. J Investig Allergol Clin Immunol. 2020 Jun 3 Epub ahead of print. PMID: 32490817. DOI:https://doi.org/10.18176/jiaci.0541.
   Google Scholar
• Call JE, Sahni S, Zug KA. Effectiveness of dupilumab in the treatment of both atopic dermatitis and alopecia universalis. Clin Case Rep. 2020 May 25;8(8):1337–1339. PMID: 32884748; PMCID: PMC7455431.
   PubMed Web of Science ®Google Scholar
• Patruno C, Napolitano M, Ferrillo M, et al. Dupilumab and alopecia: a Janus effect. Dermatol Ther. 2019 Sep;32(5):e13023. Epub 2019 Jul 24. PMID: 31306557.
   PubMed Web of Science ®Google Scholar
• Harada K, Irisawa R, Ito T, et al. The effectiveness of dupilumab in patients with alopecia areata who have atopic dermatitis: a case series of seven patients. Br J Dermatol. 2020 Aug;183(2):396–397. Epub 2020 Apr 8. PMID: 32118289.
   PubMed Web of Science ®Google Scholar
• Barbarin C, Hosteing S, Nosbaum A, et al. Early onset of alopecia areata after dupilumab introduction in a patient with atopic dermatitis. Eur J Dermatol. 2019 Oct 1;29(5):542–543. PMID: 31789276.
   PubMed Web of Science ®Google Scholar
• Kanda N, Koto M, Hoashi T, et al. Case of alopecia areata during dupilumab treatment for atopic dermatitis. J Dermatol. 2019 Sep;46(9):e332–e333. Epub 2019 Apr 3. PMID: 30942915.
   PubMed Web of Science ®Google Scholar
• Barroso-García B, Rial MJ, Molina A, et al. Alopecia areata in severe atopic dermatitis treated with dupilumab. J Investig Allergol Clin Immunol. 2018 Dec;28(6):420–421. PMID: 30530389.
   PubMed Web of Science ®Google Scholar
• Yazdanyar S, Jemec GBE. Alopecia areata after treatment with dupilumab. Dermatitis. 2019 Mar/ Apr;30(2):175–176. PMID: 30829800.
   PubMed Web of Science ®Google Scholar
• Mitchell K, Levitt J. Alopecia areata after dupilumab for atopic dermatitis. JAAD Case Rep. 2018 Jan 16;4(2):143–144. PMID: 29387767; PMCID: PMC5790019.
   PubMedGoogle Scholar
• Flanagan K, Sperling L, Lin J. Drug-induced alopecia after dupilumab therapy. JAAD Case Rep. 2018 Dec 6;5(1):54–56. PMID: 30560185; PMCID: PMC6289959.
   PubMedGoogle Scholar
• Chung J, Slaught CL, Simpson EL. Alopecia areata in 2 patients treated with dupilumab: new onset and worsening. JAAD Case Rep. 2019 Jul 30;5(8):643–645. PMID: 31388527; PMCID: PMC6675971.
   PubMedGoogle Scholar
• Carnicle JM, Hendricks AJ, Shi VY. Reactivation of alopecia areata after dupilumab therapy for atopic dermatitis. Dermatitis. 2019 Aug 21. Epub ahead of print. PMID: 31441782. DOI:https://doi.org/10.1097/DER.0000000000000512
   Google Scholar
• Ständer S, Trense Y, Thaçi D, et al. Alopecia areata development in atopic dermatitis patients treated with dupilumab. J Eur Acad Dermatol Venereol. 2020 Oct;34(10):e612–e613. Epub 2020 May 19. PMID: 32311803.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Treatment of alopecia areata (AA) with dupilumab in patients with and without atopic dermatitis (AD) 2020. U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03359356.
   Google Scholar
• Dhingra N, Shemer A, Correa Da Rosa J, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J Allergy Clin Immunol. 2014 Aug;134(2):362–372. Epub 2014 Apr 25. PMID: 24768652.
   PubMed Web of Science ®Google Scholar
• Owen JL, Vakharia PP, Silverberg JI. The role and diagnosis of allergic contact dermatitis in patients with atopic dermatitis. Am J Clin Dermatol. 2018 Jun;19(3):293–302. PMID: 29305764; PMCID: PMC5948135.
   PubMed Web of Science ®Google Scholar
• Jacob SE, Sung CT, Machler BC. Dupilumab for systemic allergy syndrome with dermatitis. Dermatitis. 2019 Mar/ Apr;30(2):164–167. PMID: 30829809.
   PubMed Web of Science ®Google Scholar
• Joshi SR, Khan DA. Effective use of dupilumab in managing systemic allergic contact dermatitis. Dermatitis. 2018 Sep/ Oct;29(5):282–284. PMID: 30179979.
   PubMed Web of Science ®Google Scholar
• Goldminz AM, Scheinman PL. A case series of dupilumab-treated allergic contact dermatitis patients. Dermatol Ther. 2018 Nov;31(6):e12701. Epub 2018 Sep 24. PMID: 30246906.
   PubMed Web of Science ®Google Scholar
• Chipalkatti N, Lee N, Zancanaro P, et al. Dupilumab as a treatment for allergic contact dermatitis. Dermatitis. 2018 Nov/ Dec;29(6):347–348. PMID: 30346326.
   PubMed Web of Science ®Google Scholar
• Zhu GA, Chen JK, Chiou A, et al. Repeat patch testing in a patient with allergic contact dermatitis improved on dupilumab. JAAD Case Rep. 2019 Apr 3;5(4):336–338. PMID: 30989102; PMCID: PMC6447730.
   PubMedGoogle Scholar
• Ruge IF, Skov L, Zachariae C, et al. Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones. Contact Dermatitis. 2020 Aug;83(2):137–139. Epub 2020 Apr 20. PMID: 32243595.
   PubMed Web of Science ®Google Scholar
• Crepy MN, Nosbaum A, Bensefa-Colas L. Blocking type 2 inflammation by dupilumab does not control classic (type 1-driven) allergic contact dermatitis in chronic hand eczema. Contact Dermatitis. 2019 Aug;81(2):145–147. Epub 2019 Apr 10. PMID: 30851059.
   PubMed Web of Science ®Google Scholar
• Hoot JW, Douglas JD, Falo LD Jr. Patch testing in a patient on dupilumab. Dermatitis. 2018 May/ Jun;29(3):164. PMID: 29570490.
   PubMed Web of Science ®Google Scholar
• Puza CJ, Atwater AR. Positive patch test reaction in a patient taking dupilumab. Dermatitis. 2018 Mar/ Apr;29(2):89. PMID: 29494389.
   PubMed Web of Science ®Google Scholar
• Machler BC, Sung CT, Darwin E, et al. Dupilumab use in allergic contact dermatitis. J Am Acad Dermatol. 2019 Jan;80(1):280–281. e1. Epub 2018 Aug 6. PMID: 30092326.
   PubMed Web of Science ®Google Scholar
• Chipalkatti N, Lee N, Zancanaro P, et al. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis. J Am Acad Dermatol. 2019 Apr;80(4):1166–1167. Epub 2019 Jan 8. PMID: 30630024.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. The effects of dupilumab on allergic contact dermatitis. U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03935971.
   Google Scholar
• Agner T, Elsner P. Hand eczema: epidemiology, prognosis and prevention. J Eur Acad Dermatol Venereol. 2020;34(Suppl 1):4–12.
   PubMedGoogle Scholar
• Diepgen TL. Occupational skin-disease data in Europe. Int Arch Occup Environ Health. 2003;76: pp. 331–338.
   PubMed Web of Science ®Google Scholar
• Agner T, Andersen KE, Brandao FM, et al. Hand eczema severity and quality of life: a cross-sectional, multicentre study of hand eczema patients. Contact Dermatitis. 2008 Jul;59(1):43–47. PMID: 18537992.
   PubMed Web of Science ®Google Scholar
• Molin S, Diepgen TL, Ruzicka T, et al. Diagnosing chronic hand eczema by an algorithm: a tool for classification in clinical practice. Clin Exp Dermatol. 2011 Aug;36(6):595–601. PMID: 21771004.
   PubMed Web of Science ®Google Scholar
• Oosterhaven JAF, Voorberg AN, Romeijn GLE, et al. Effect of dupilumab on hand eczema in patients with atopic dermatitis: an observational study. J Dermatol. 2019 Aug;46(8):680–685. Epub 2019 Jun 12. PMID: 31187925; PMCID: PMC6771665.
   PubMed Web of Science ®Google Scholar
• Zirwas MJ. Dupilumab for hand eczema. J Am Acad Dermatol. 2018 Jul;79(1):167–169. Epub 2018 Mar 10. PMID: 29535032.
   PubMed Web of Science ®Google Scholar
• Zhu GA, Honari G, Ko JM, et al. Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: a case report. JAAD Case Rep. 2020 Mar 25;6(4):296–298. PMID: 32258302; PMCID: PMC7109358.
   PubMedGoogle Scholar
• Loman L, Diercks GFH, Schuttelaar MLA. Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab. Contact Dermatitis. 2020 Aug 30. Epub ahead of print. PMID: 32864776. DOI:https://doi.org/10.1111/cod.13693
   Web of Science ®Google Scholar
• Oosterhaven JAF, Romeijn GLE, Schuttelaar MLA. Dupilumab treatment of very severe refractory atopic hand eczema. JAMA Dermatol. 2018 Aug 1;154(8):969–970. PMID: 29971331.
   PubMed Web of Science ®Google Scholar
• Lee N, Chipalkatti N, Zancanaro P, et al. A retrospective review of dupilumab for hand dermatitis. Dermatology. 2019;235(3):187–188. Epub 2019 Feb 6. PMID: 30726838.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Dupilumab in severe chronic hand eczema (DUPSHE). U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04512339.
   Google Scholar
• ClinicalTrials.gov. Efficacy and safety of dupilumab chronic hands eczema refractory to highly potent topical corticosteroids (DUPECZEMAIN). U.S. National Library of Medicine. [cited 2020 Dec 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT03861455.
   Google Scholar
• Waldman RA, DeWane ME, Sloan B, et al. Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients. J Am Acad Dermatol. 2020 May;82(5):1251–1252. Epub 2020 Jan 8. PMID: 31926220.
   PubMed Web of Science ®Google Scholar
• Weston GK, Hooper J, Strober BE. Dupilumab in the treatment of dyshidrosis: a report of two cases. J Drugs Dermatol. 2018 Mar 1;17(3):355–356. PMID: 29537454.
   PubMed Web of Science ®Google Scholar
• Nanda S, Nagrani N, MacQuhae F, et al. A case of complete resolution of severe plantar dyshidrotic eczema with dupilumab. J Drugs Dermatol. 2019 Feb 1;18(2):211–212. PMID: 30811150.
   PubMed Web of Science ®Google Scholar
• Weins AB, Biedermann T, Eyerich K, et al. Successful treatment of recalcitrant dyshidrotic eczema with dupilumab in a child. J Dtsch Dermatol Ges. 2019 Nov;17(11):1165–1167. Epub 2019 Oct 14. PMID: 31612565.
   Web of Science ®Google Scholar
• Andreasen TH, Karstensen HG, Duno M, et al. Successful treatment with dupilumab of an adult with Netherton syndrome. ClinExpDermatol. 2020 May 30 Epub ahead of print. PMID: 32472705. DOI:https://doi.org/10.1111/ced.14317.
   Google Scholar
• Steuer AB, Cohen DE. Treatment of Netherton syndrome with dupilumab. JAMA Dermatol. 2020 Mar 1;156(3):350–351. PMID: 31995125.
   PubMed Web of Science ®Google Scholar
• Süßmuth K, Traupe H, Loser K, et al. Response to dupilumab in two children with Netherton syndrome: improvement of pruritus and scaling. J EurAcad Dermatol Venereol. 2020 Aug 18 Epub ahead of print. PMID: 32810299. DOI:https://doi.org/10.1111/jdv.16883.
   Google Scholar
• Aktas M, Salman A, AptiSengun O, et al. Netherton syndrome: temporary response to dupilumab. PediatrDermatol. 2020 Sep 19 Epub ahead of print. PMID: 32951242. DOI:https://doi.org/10.1111/pde.14362.
   Google Scholar
• Cuevas-Gonzalez JC, Lievanos-Estrada Z, Vega-Memije ME, et al. Correlation of serum IgE levels and clinical manifestations in patients with actinic prurigo. An Bras Dermatol. 2016 Jan-Feb;91(1):23–26. PMID: 26982774; PMCID: PMC4782642.
   PubMed Web of Science ®Google Scholar
• Verma L, Pratt M. A case report of therapeutically challenging chronic actinic dermatitis. SAGE Open Med Case Rep. 2019 May 2;7:2050313X19845235.
   PubMed Web of Science ®Google Scholar
• Smith MP, Ly K, Thibodeaux Q, et al. Dupilumab for the treatment of severe photodermatitis. JAAD Case Rep. 2019 Jul 12;5(7):614–616. PMID: 31341939; PMCID: PMC6629719.
   PubMedGoogle Scholar
• Eickstaedt JB, Starke S, Krakora D, et al. Clearance of pediatric actinic prurigo with dupilumab. PediatrDermatol. 2020 Aug 31. Epub ahead of print. PMID: 32869345. DOI:https://doi.org/10.1111/pde.14311
   Google Scholar
• Teraki Y, Inoue Y. Skin-homing Th2/Th22 cells in papuloerythroderma of Ofuji. Epub 2014 Apr 11. PMID: 24732450 Dermatology. 2014;2284:326–331.
   PubMed Web of Science ®Google Scholar
• Teraki Y, Taguchi R, Takamura S, et al. Use of dupilumab in the treatment of papuloerythroderma of Ofuji. JAMA Dermatol. 2019 Jun 19;155(8):979. Epub ahead of print. PMID: 31215964.
   PubMed Web of Science ®Google Scholar
• Komatsu-Fujii T, Nonoyama S, Ogawa M, et al. Rapid effects of dupilumab treatment on papuloerythroderma of Ofuji. J EurAcad Dermatol Venereol. 2020 May 7 Epub ahead of print. PMID: 32379915. DOI:https://doi.org/10.1111/jdv.16581.
   Google Scholar
• Sempau L, Larralde M, Luna PC, et al. Eosinophilic annular erythema. Dermatol Online J. 2012 Mar 15;18(3):8. PMID: 22483519.
   PubMedGoogle Scholar
• Gordon SC, Robinson SN, Abudu M, et al. Eosinophilic annular erythema treated with dupilumab. PediatrDermatol. 2018 Jul;35(4):e255–e256. Epub 2018 May 23. PMID: 29790187.
   Google Scholar
• Maione V, Caravello S, Cozzi C, et al. Refractory eosinophilic annular erythema treated successfully with dupilumab. J Dtsch Dermatol Ges. 2020 Sep;18(9):1031–1032. Epub 2020 Sep 10. PMID: 32909389.
   Web of Science ®Google Scholar
• Shehadeh W, Sarig O, Bar J. Sprecher E. et al. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020 Jun;182(6):1495–1497. Epub 2020 Jan 29. PMID: 3189982.
   PubMed Web of Science ®Google Scholar